DEM BioPharma is an immuno-oncology company focused on developing innovative therapies aimed at eradicating cancer by targeting the innate immune system. The company has created a platform that specializes in the next generation of macrophage immunotherapies, which work by activating macrophages and immune phagocytes to effectively eliminate tumors. By researching and harnessing these immune responses, DEM BioPharma aims to provide healthcare researchers with advanced treatments that specifically target signals on both cancer cells and macrophages, offering new hope in the fight against cancer.
Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas.
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.
Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.
ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Interius BioTherapeutics
Series A in 2021
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.
Renovia Inc., founded in 2016 and headquartered in Boston, Massachusetts, operates in the healthcare sector, focusing on the development of medical devices aimed at alleviating incontinence in women. The company specializes in creating both diagnostic and therapeutic devices for women suffering from pelvic floor disorders. Renovia's mission is to improve the quality of life for women dealing with these common yet often overlooked health issues.
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.
ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
XyloCor Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Established in 2013 and based in Newtown Square, Pennsylvania, the company is working on innovative treatments such as XC001, an investigational gene therapy aimed at patients suffering from refractory angina who have limited treatment options, and XC002, which targets cardiac tissue regeneration in individuals with compromised heart function due to past heart attacks. XyloCor's approach involves stimulating the formation of new coronary blood vessels to improve blood supply to areas of the heart that are inadequately perfused, thereby offering potential pain relief and improved outcomes for patients who have exhausted conventional pharmacologic therapies.
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
Lassen Therapeutics focuses on developing antibody biotherapeutics aimed at treating fibrosis, rare diseases, and cancer. The company's lead candidate, LASN01, is a monoclonal antibody that specifically targets the IL-11 receptor alpha, which is a key mediator in fibrosis and tumor growth. By inhibiting IL-11, Lassen Therapeutics aims to offer a more effective treatment alternative compared to traditional approaches that target other factors like TGF-β and CTGF. The company leverages advanced antibody technologies to create innovative therapeutics that address the complexities of the tumor microenvironment and the role of cytokines in various diseases, ultimately striving to enhance patient outcomes for those affected by serious health conditions.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
ArcherDX, Inc. is a genomics company based in Boulder, Colorado, focused on advancing molecular pathology through next-generation sequencing technology. Established in 2013, the company develops and commercializes a range of research products, including DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex, and RNA-based Immunoverse, aimed at optimizing therapy and monitoring cancer. ArcherDX also creates in-vitro diagnostic products and offers customizable assay design services to clinical and biopharmaceutical clients, enabling the development of new applications tailored to specific biomarker targets. The Archer platform utilizes proprietary Anchored Multiplexed PCR (AMP™) chemistry and sophisticated bioinformatics to enhance genetic mutation detection significantly. The company's products and services are utilized by academic and reference laboratories, biopharmaceutical firms, and contract research organizations, with ongoing efforts to gain regulatory approval for various companion diagnostic assays. As of October 2020, ArcherDX operates as a subsidiary of Invitae Corporation.
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.
ArcherDX, Inc. is a genomics company based in Boulder, Colorado, focused on advancing molecular pathology through next-generation sequencing technology. Established in 2013, the company develops and commercializes a range of research products, including DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex, and RNA-based Immunoverse, aimed at optimizing therapy and monitoring cancer. ArcherDX also creates in-vitro diagnostic products and offers customizable assay design services to clinical and biopharmaceutical clients, enabling the development of new applications tailored to specific biomarker targets. The Archer platform utilizes proprietary Anchored Multiplexed PCR (AMP™) chemistry and sophisticated bioinformatics to enhance genetic mutation detection significantly. The company's products and services are utilized by academic and reference laboratories, biopharmaceutical firms, and contract research organizations, with ongoing efforts to gain regulatory approval for various companion diagnostic assays. As of October 2020, ArcherDX operates as a subsidiary of Invitae Corporation.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.
Sitryx Therapeutics is a biopharmaceutical company established in 2018 and based in Oxford, United Kingdom. It focuses on developing disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. The company aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by renowned scientists from the United States and Europe, Sitryx has garnered significant funding, including a $30 million Series A round from various specialist investors. The company is actively engaged in multiple stages of drug discovery, working on a diverse pipeline of projects aimed at addressing unmet medical needs in immunometabolism.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Renovia Inc., founded in 2016 and headquartered in Boston, Massachusetts, operates in the healthcare sector, focusing on the development of medical devices aimed at alleviating incontinence in women. The company specializes in creating both diagnostic and therapeutic devices for women suffering from pelvic floor disorders. Renovia's mission is to improve the quality of life for women dealing with these common yet often overlooked health issues.
Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.
ArcherDX, Inc. is a genomics company based in Boulder, Colorado, focused on advancing molecular pathology through next-generation sequencing technology. Established in 2013, the company develops and commercializes a range of research products, including DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex, and RNA-based Immunoverse, aimed at optimizing therapy and monitoring cancer. ArcherDX also creates in-vitro diagnostic products and offers customizable assay design services to clinical and biopharmaceutical clients, enabling the development of new applications tailored to specific biomarker targets. The Archer platform utilizes proprietary Anchored Multiplexed PCR (AMP™) chemistry and sophisticated bioinformatics to enhance genetic mutation detection significantly. The company's products and services are utilized by academic and reference laboratories, biopharmaceutical firms, and contract research organizations, with ongoing efforts to gain regulatory approval for various companion diagnostic assays. As of October 2020, ArcherDX operates as a subsidiary of Invitae Corporation.
Recros Medica, Inc., medical device company, develops technologies to treat skin laxity and focal aesthetic contour deformities. It offers Rotational Fractional Resection, a platform for skin contouring approaches, such as traditional surgery, liposuction, energy-based devices, injectable chemical lipolytic agents, and cryolipolysis. The company also provides Focal Contouring System for dermatologists, plastic surgeons, and other aesthetic physicians. Recros Medica, Inc. was incorporated in 2014 and is based in San Diego, California.
Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.
Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.
Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Colorescience, Inc. specializes in the production and sale of mineral-based cosmetics and sunscreen products. Founded in 2000 and based in Carlsbad, California, the company offers a range of treatment products aimed at addressing various skin concerns, including pigmentation, redness, dark circles, and signs of aging, as well as catering to different skin types such as sensitive, oily, and dry skin. Its product line includes UV protectors, primers, foundations, and enhancers, all designed with high-quality ingredients and formulations. Colorescience distinguishes itself in the luxury aesthetic makeup market by focusing on efficacy and ease of use. The company distributes its products through a network of licensed physicians, luxury spas, retailers, and online channels, emphasizing its commitment to reducing skin cancer and other skin conditions.
Colorescience, Inc. specializes in the production and sale of mineral-based cosmetics and sunscreen products. Founded in 2000 and based in Carlsbad, California, the company offers a range of treatment products aimed at addressing various skin concerns, including pigmentation, redness, dark circles, and signs of aging, as well as catering to different skin types such as sensitive, oily, and dry skin. Its product line includes UV protectors, primers, foundations, and enhancers, all designed with high-quality ingredients and formulations. Colorescience distinguishes itself in the luxury aesthetic makeup market by focusing on efficacy and ease of use. The company distributes its products through a network of licensed physicians, luxury spas, retailers, and online channels, emphasizing its commitment to reducing skin cancer and other skin conditions.
Flex Pharma, Inc. is a biotechnology company focused on developing and commercializing treatments for muscle cramps, spasms, and spasticity linked to neurological conditions and exercise. The company operates in two segments: Consumer Operations and Drug Development. Its lead drug candidate, FLX-787, is a dual transient receptor potential V1/A1 ion channel activator, which has completed an exploratory Phase II clinical trial in Australia targeting multiple sclerosis patients. Additionally, Flex Pharma offers HOTSHOT, a consumer beverage designed to prevent and treat exercise-associated muscle cramps. The company markets HOTSHOT products online through its direct-to-consumer website and third-party platforms that provide international shipping. Founded in 2014 and based in Boston, Massachusetts, Flex Pharma was acquired by Salarius Pharmaceuticals in 2019.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics for cancer treatment. The company focuses on targeting tumor metabolism and tumor immunology to create innovative anti-cancer drugs. Its lead product candidate, CB-839, is an inhibitor of glutaminase currently undergoing Phase II clinical trials for solid tumors. Additionally, Calithera is developing CB-1158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology indications. The company is also working on other candidates, including CB-280 for cystic fibrosis and CB-708, an inhibitor of CD73. Calithera has established collaborations with major pharmaceutical firms, including Bristol-Myers Squibb and Incyte Corporation, to advance its research and development efforts. Founded in 2010, Calithera aims to address critical challenges in cancer therapy through its specialized drug development pipeline.
Mitobridge, Inc., a biotechnology company, discovers and develops novel small molecule therapeutics that improve mitochondrial functions. Its product under pipeline includes MA-0211 (MTB-1), a clinical compound that is orally bioavailable PPARd modulator that aims to reverse the mitochondrial deficits in Duchenne muscular dystrophy patients. Mitobridge, Inc. was formerly known as Mitokyne, Inc. and changed its name to Mitobridge, Inc. in February 2015. The company was incorporated in 2011 and is based in Cambridge, Massachusetts. As of January 23, 2018, Mitobridge, Inc. operates as a subsidiary of Astellas Pharma Inc.
Private Equity Round in 2013
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
Alnara Pharmaceuticals, Inc. specializes in the development and commercialization of novel protein therapeutics aimed at treating metabolic diseases. The company employs an innovative approach that emphasizes the design of effective protein therapies capable of being orally delivered directly to the gastrointestinal tract, ensuring they are not absorbed into the bloodstream. This unique method positions Alnara to address unmet medical needs in the realm of metabolic disorders through advanced therapeutic solutions.
Alnara Pharmaceuticals, Inc. specializes in the development and commercialization of novel protein therapeutics aimed at treating metabolic diseases. The company employs an innovative approach that emphasizes the design of effective protein therapies capable of being orally delivered directly to the gastrointestinal tract, ensuring they are not absorbed into the bloodstream. This unique method positions Alnara to address unmet medical needs in the realm of metabolic disorders through advanced therapeutic solutions.
IlluminOss Medical, Inc. is a medical device company specializing in the development of minimally invasive orthopedic systems for fracture repair and stabilization. Founded in 2007 and based in East Providence, Rhode Island, the company offers a unique technology that utilizes a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants. This innovative approach is particularly beneficial for treating osteoporotic and compromised bone, providing a fast and effective method for bone stabilization. The IlluminOss system is CE-marked and FDA-cleared for use in various anatomical sites, with additional indications currently under review. IlluminOss markets its products through distributors in several countries, including Austria, Germany, Israel, and the United Kingdom.